[In vitro resistance of Candida species to antifungal agents]

W Banach-Piatkowska1, A Kotłowski, J Humanowska

  • 1Zakład Medycyny Tropikalnej Instytutu Medycyny Morskiej i Tropikalnej w Gdyni 81-519 Gdynia, ul. Powstania Styczniowego 9b.

Insights

Most Candida species showed susceptibility to polyenes (91.6%) but fewer to azoles (32.9%). Antifungal resistance varied by fungal species and sample type, highlighting the need for susceptibility monitoring.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Clinical Microbiology

Background:

  • Fungal infections caused by Candida species are a significant global health concern.
  • Antifungal resistance is an emerging challenge in treating these infections.
  • Understanding the susceptibility patterns of Candida isolates is crucial for effective treatment strategies.

Purpose of the Study:

  • To evaluate the in vitro susceptibility of clinical Candida isolates to six antifungal agents.
  • To determine the prevalence of resistance to polyenes and azoles among these isolates.
  • To explore the relationship between antifungal susceptibility, fungal species, and clinical sample source.

Main Methods:

  • Analysis of 143 Candida strains isolated from 545 patients suspected of fungal infections.
  • In vitro susceptibility testing using the ATB Fungus (bioMérieux) commercial assay.
  • Categorization of susceptibility based on resistance to polyenes and azoles.

Main Results:

  • High susceptibility (91.6%) was observed for polyenes, while lower susceptibility (32.9%) was noted for azoles against all Candida isolates.
  • Low percentages of resistance were found for polyenes (0.7% to 4.2%), contrasting with higher rates for azoles (32.9% to 41.2%).
  • Antifungal resistance patterns were found to be dependent on the clinical sample source and the specific Candida species.

Conclusions:

  • The study demonstrates significant variations in Candida susceptibility to different antifungal classes.
  • The ATB Fungus test is a valuable tool for monitoring antifungal susceptibility in clinical settings.
  • Tailoring antifungal therapy based on susceptibility data is essential for optimizing patient outcomes.

Related Concept Videos

Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...